Engineered TCR Specificity for Leukemia Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy methods face challenges in effectively targeting leukemia cells due to the lack of specific antigens and the risk of systemic graft-versus-host disease (GVHD) associated with traditional approaches.
Innovation Solution
Development of T-cell receptors (TCRs) with antigenic specificity for CD1c molecules associated with self-lipids, such as methyl-lysophosphatidic acids, which are selectively expressed on leukemia cells, allowing for targeted recognition and destruction of leukemia cells while minimizing damage to normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cancer immunotherapy approaches are used to target leukemia cells, then therapeutic efficacy may be achieved, but the risk of systemic graft-versus-host disease (GVHD) increases
Solution Approach 1:
The TCR is engineered with specific variable regions (CDR1, CDR2, CDR3 of both alpha and beta chains) that confer selective recognition of mLPA-CD1c complexes. This localized specificity at the antigen-binding site enables targeted killing of leukemia cells expressing CD1c-mLPA while sparing normal cells that do not express this complex, thereby achieving therapeutic efficacy without systemic GVHD
Solution Approach 2:
The TCR is divided into distinct functional domains: variable regions for antigen recognition (with six CDRs that provide specificity), constant regions for signal transduction, and engineered sequences for optimal expression. This segmentation allows independent optimization of each domain - the variable regions are designed for specific mLPA-CD1c recognition while the constant regions maintain proper T cell signaling function
2Object-affected harmful factors
If T cells are engineered to recognize specific leukemia antigens, then targeted destruction of leukemia cells is achieved, but the complexity of the therapy increases
Solution Approach 1:
The natural TCR alpha and beta chain sequences that specifically recognize mLPA-CD1c complexes are cloned and replicated in vitro. These copied TCR sequences are then introduced into allogeneic T cells, creating standardized therapeutic products that can be manufactured consistently without requiring complex personalized engineering for each patient
Solution Approach 2:
The patent uses viral vectors as intermediary carriers to deliver the TCR-encoding nucleic acids into T cells. This intermediary approach simplifies the engineering process by using well-established viral transduction methods rather than requiring complex CRISPR-Cas9 genome editing or other advanced genetic manipulation techniques
3Productivity
If allogeneic T cells are used for immunotherapy, then large quantities of tumor-reactive T cells can be generated, but the risk of host rejection increases
Solution Approach 1:
The antigen-specific recognition function is extracted from the entire T cell and concentrated into the engineered TCR molecule. By transferring only the specific TCR sequences into allogeneic T cells, the therapy achieves high productivity using off-the-shelf allogeneic cells while the extracted TCR specificity prevents host rejection by ensuring the T cells recognize only leukemia antigens and not host tissues
Data Source
AI summary
The present invention relates to a TCR or functional variant thereof having antigenic specificity for CD1c molecules associated with a self-lipid, preferably (mLPA) or derivative thereof, to relative polypeptide, protein, nucleic acid, recombinant expression vector, host cell, population of cells, antibody and pharmaceutical composition. The present invention also relates to the uses of said TCR and relative products, in particular for use in the treatment and/or prevention of an hematological disorder.